Pressemitteilung BoxID: 64012 (Gene Bridges GmbH)
  • Gene Bridges GmbH
  • Im Neuenheimer Feld 584
  • 69120 Heidelberg
  • Ansprechpartner
  • Gary Stevens
  • +49(0)6221 13708-10

Gene Bridges collaborates with High Q Foundation for Huntington Disease Models

(PresseBox) (Heidelberg, ) Gene Bridges announced today that it is supplying the High Q Foundation with optimized targeting vectors to generate mouse models used in their research aimed at curing Huntington Disease. Gene Bridges applies its proprietary Red/ET recombination technology, which allows the engineering of large DNA sequences with single-nucleotide precision for the generation of the necessary DNA vectors.

“We are very proud that the High Q Foundation has chosen our services for the cloning of the targeting constructs. The possibility to address modifications at every single nucleotide in a large DNA fragment by Red/ET recombination technology allows us to assist our customers in generating transgenic mouse models, which are perfectly optimized for their research. It is very satisfying for us that we can support the efforts to find treatments against so far incurable illnesses like Huntington,” said Dr. Harald Kranz, Head of Gene Bridges’ Service Unit.

About Huntington Disease

Huntington Disease is a familial disease, passed from parent to child through a mutation in a gene which causes programmed degeneration of brain cells and results in emotional disturbance, loss of intellectual faculties and uncontrolled movements. It is estimated that about one in every 10,000 persons has the Huntington Disease gene. At this time, there is no way to stop or reverse the course of Huntington Disease.

About High Q Foundation

The High Q Foundation (High Q) is a non-profit organization with the mission of understanding the pathophysiology of Huntington disease in order to rapidly identify, evaluate and validate targets for therapeutic intervention and to develop tools needed for target discovery, drug development and clinical trials. High Q brings together the scientific community including academia, industry, governmental agencies, and other funding organizations in a collaborative network to focus on research with a potential route to therapy. For more information please see

Gene Bridges GmbH

Gene Bridges GmbH is a self-funded biotech company, which develops and commercializes innovative DNA engineering technologies. Its patented Red/ET Recombination, also known as lambda-red mediated recombination or recombineering, enables cloning and precise modification of DNA molecules regardless of restriction sites and is particularly useful for the rapid generation of targeting vectors necessary to create transgenic mouse models. Other application areas are the modification of BACs (bacterial artificial chromosomes) and the E. coli genome, as well as viral engineering. For more information, visit:

Für die oben stehenden Pressemitteilungen, das angezeigte Event bzw. das Stellenangebot sowie für das angezeigte Bild- und Tonmaterial ist allein der jeweils angegebene Herausgeber (siehe Firmeninfo bei Klick auf Bild/Meldungstitel oder Firmeninfo rechte Spalte) verantwortlich. Dieser ist in der Regel auch Urheber der Pressetexte sowie der angehängten Bild-, Ton- und Informationsmaterialien.
Die Nutzung von hier veröffentlichten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Bei Veröffentlichung senden Sie bitte ein Belegexemplar an